J&J, Other Q1 Financials Beg the Queston: What Does It Mean to Miss Expectations? 4/19/2024

Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies 4/19/2024

A novel approach to drug discovery is enabling University of Birmingham researchers to overcome the 'valley of death', where projects fail due to the funding gap between original research and commercial investment.

The approach, detailed in a feature published in the April issue of Drug Discovery Today, has attracted more than £4m in industry funding, grants and industry awards, on the back of just £0.2m investment from the University's Dynamic Investment Fund (DIF).

Weight-Loss Drug Startup Metsera Launches with $290M, Looks to Tap Lucrative Obesity Market 4/18/2024

Intra-Cellular Looks to Raise $500M in Public Offering Following Phase III MDD Win 4/18/2024

Cerevel Gets Phase III Parkinson’s Win on Heels of $8.7B AbbVie Acquisition 4/18/2024

Most Doses of Lilly’s Zepbound and Mounjaro in Short Supply Through Q2: FDA 4/18/2024

Teva, Alvotech Secure FDA Approval for Stelara Biosimilar with Early 2025 Launch 4/18/2024

Roche’s Ocrevus Achieves Near-Complete Reduction of Relapse, Lesions in MS 4/18/2024

Bioversity Program Preps Grads for Early-Career Life Science Roles 4/18/2024

How to Deal With Layoff-Related Stress 4/18/2024

Career Coach: How to Look Professional in Virtual Meetings 4/18/2024

5 Top Companies Hiring Oncology Jobs 4/18/2024

Alzheimer's disease (AD) currently afflicts nearly seven million people in the U.S. With this number expected to grow to nearly 13 million by 2050, the lack of meaningful therapies represents a major unmet medical need. Scientists at Sanford Burnham Prebys have now identified promising real-world links between common HIV drugs and a reduced incidence of AD. The study, led by Jerold Chun, M.D., Ph.D., was published in Pharmaceuticals.

Chun's new research builds on his lab's landmark publication in Nature in 2018 that described how somatic gene recombination in neurons can produce thousands of new gene variants within Alzheimer's disease brains.

Lilly Eyes Zepbound Label Expansion After Clearing Phase III Sleep Apnea Study 4/17/2024

Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop 4/17/2024

Amylyx Sheds More Light on Relyvrio’s Late-Stage Trial Failure in ALS 4/17/2024

Amylyx at a Crossroads: Can the Company Overcome the Loss of Relyvrio? 4/17/2024

Arvinas Strikes Deals With Pfizer, Novartis to Compete in Protein Degrader Space 4/17/2024

Top Q1 Series A Investments Highlight VC Rebound in Biopharma 4/17/2024